Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies

NCT03663712 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
28
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Dan Blazer III, M.D.